Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc5)
- Development stage
- Unknown
- Lead developer
- Allergy Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
Pollinex Quattro Ragweed is an ultra-short-course allergy vaccine developed by Allergy Therapeutics for the treatment of seasonal allergic rhinitis caused by ragweed pollen. It consists of a ragweed pollen extract that has been chemically modified with glutaraldehyde to form an allergoid, which reduces its allergenicity while maintaining its ability to stimulate the immune system. The allergoid is adsorbed onto L-tyrosine, which serves as a slow-release depot, and is combined with the immunostimulatory adjuvant monophosphoryl lipid A (MPL). MPL is a Toll-like receptor 4 (TLR4) agonist that helps direct the immune response toward a Th1 profile, potentially leading to long-term desensitization. The treatment is administered as a series of four subcutaneous injections given before the start of the ragweed pollen season.
- Brand names
- Pollinex Quattro Ragweed
- Other names
- Ragweed Pollen Allergoid Tyrosine Adsorbate with MPL
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc5).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pollinex Quattro Ragweed (Allergy Therapeutics PLC, c2bcc5).